Evidence-based · Peptides
Sermorelin: What the Research Shows on the GHRH Analog
A once-approved GHRH analog that nudges your own growth hormone. Real pharmacology, thin longevity evidence, now a compounded product.
Part ofThe Research-Peptide Directory→Sermorelin is marketed today as an anti-aging peptide — a way to raise growth hormone (GH), lean muscle, and sleep quality without injecting GH directly. The pharmacology behind that pitch is real and well understood. The evidence that it delivers meaningful benefits in healthy adults is not. It is also worth knowing that sermorelin was once an FDA-approved drug and no longer is — a detail the longevity marketing rarely mentions.
What sermorelin actually is
Sermorelin is a 29-amino-acid peptide — the shortest fully active fragment of the body’s own 44-amino-acid growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on the pituitary and prompts the gland to make and release its own GH, which in turn raises insulin-like growth factor 1 (IGF-1). That is the mechanistic appeal: rather than supplying GH from outside, it works through the body’s existing feedback loop, so pituitary regulation still has a say.
Sermorelin’s mechanism is genuine GHRH pharmacology — but stimulating your own GH release is not the same as proving durable benefits in healthy people.
It used to be an approved drug
This is the part most write-ups skip. The FDA approved sermorelin in 1997 under the brand name Geref, for diagnosing and treating growth hormone deficiency in children. The manufacturer withdrew it in 2008 — for business reasons, not safety. As a 2006 editorial in Clinical Interventions in Aging put it, sermorelin was marketed for years as an alternative to recombinant GH in children but “could not compete with rhGH and was withdrawn.” So the sermorelin sold today for anti-aging is not the approved drug being repurposed; it is a compounded product, prescribed off-label, with no active FDA approval behind it.
What the adult evidence shows
Give an older adult once-daily GHRH injections and their GH and IGF-1 do rise — the NIH’s Endotext review notes levels reach at least the lower range seen in young adults, with one 6-month trial reporting a 35% IGF-1 increase alongside gains in lean mass and reductions in visceral fat. That sounds like the marketing promise. The problem is what happens downstream.
| What was measured | What the studies found |
|---|---|
| GH / IGF-1 levels | Reliably increased |
| Lean body mass / visceral fat | Modest favorable shifts in some trials |
| Strength / aerobic fitness | No improvement despite hormonal gains |
| Long-term clinical outcomes | Not assessed |
The same review is blunt: “there is no consensus on functional effects among these few studies, and none have assessed long-term clinical outcomes or risks.” Trials of related GH secretagogues echo this — hormones and even fat-free mass went up without translating into measurable strength or function.
Why it matters
Raising a hormone is not the same as improving health. The human sermorelin literature is small, short, and focused on biomarkers rather than outcomes that people actually feel or that predict longevity. The trials are also mostly in adults with age-related GH decline, not the general healthy population being marketed to. And using GH itself for anti-aging is not merely unsupported — the Endotext authors note it “is not warranted and is currently prohibited by US federal law.”
The takeaway
Sermorelin is a legitimate GHRH analog with real, understood pharmacology and a genuine regulatory history — but it lost that approval, and the case for the popular longevity, body-composition, and sleep claims rests on a handful of small biomarker studies that never showed durable functional benefit. Treat it as a compounded, off-label product with interesting biology and thin outcome evidence, not a proven anti-aging tool.
Sources
Stay current
Get evidence-based briefings in your inbox.